Beyond an inhibition of the EGFR-signaling cascade, anti-EGFR IgG1-antibodies induce antibody-dependent, cell-mediated cytotoxicity (ADCC) in HNSCC and, therefore, act as an anti-cancer immunotherapeutic agent itself (14). Here, EGFR is linked to head and neck squamous cell carcinoma.